Biosimilar Hormones Market Growth Is Reshaping Competitive Advantage Across The Industry
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Biosimilar Hormones Market Expansion From $7.68 Billion In 2026 To $18.12 Billion In 2030
The biosimilar hormones market has experienced remarkable expansion in recent years, with its value projected to increase from $6.22 billion in 2025 to $7.68 billion in 2026, reflecting a compound annual growth rate (CAGR) of 23.5%. This historic growth has been driven by several factors, including the increasing incidence of diabetes and hormonal disorders, the elevated expense associated with branded hormone treatments, a growing elderly demographic, heightened awareness surrounding hormone replacement therapies, and the broader reach of hospital and retail pharmacy networks.
Over the coming years, the market for biosimilar hormones is anticipated to experience rapid and substantial expansion. By 2030, its value is projected to reach $18.12 billion, reflecting a compound annual growth rate (CAGR) of 23.9%. This forecasted surge is driven by several factors, including the expiration of patents for major biologic hormones, heightened regulatory backing for biosimilars, a rising need for cost-effective endocrine treatments, broader distribution through online pharmacies, and increased funding for biosimilar research and development. Key developments shaping this period involve a growing preference for biosimilar hormones as more affordable treatment options, a heightened demand for biosimilars of insulin and growth hormones, greater physician confidence in these therapies, their expanding role in managing chronic and lifestyle-related conditions, and more streamlined regulatory processes that facilitate their approval.
Download A Free Sample Report For Comprehensive Market Insights:
Biosimilar Hormones Market Growth Factors Supporting Long-Term Expansion
The upward trajectory of healthcare spending is anticipated to drive expansion in the biosimilar hormones market during the forecast period. Healthcare expenditure encompasses all financial resources allocated by individuals, organizations, or governments toward preventing, treating, and managing health conditions. This spending is on the rise because of improvements in medical technology, where novel diagnostic tools, treatments, and cutting-edge therapies frequently carry higher costs, thereby increasing overall spending in the healthcare sector. Growing healthcare costs are boosting the adoption of biosimilar hormones by fueling demand for economical treatment options and broadening patient availability across various healthcare systems. As an example, in December 2024, the Centers for Medicare & Medicaid Services—a U.S. agency overseeing Medicare and Medicaid programs—reported that American healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, which equates to roughly $14,570 per person. Consequently, the rise in healthcare spending is propelling growth within the biosimilar hormones market.
Biosimilar Hormones Market Driver: Rising Diabetes Epidemic Fuels Growth In Biosimilar Hormones Market
Escalating diabetes rates are expected to fuel expansion in the biosimilar hormones market moving forward. Diabetes represents a chronic medical condition that affects how the body processes food for energy. Biosimilar hormones such as insulin provide safe and effective options for diabetes management, potentially leading to lower costs and enhanced patient accessibility. Biosimilar growth hormone can assist in diabetes treatment by improving blood sugar regulation in adults diagnosed with type 1 and type 2 diabetes. To illustrate, in June 2023, the International Diabetes Federation (IDF)—a Germany-based umbrella organization covering more than 240 national diabetes groups—noted a substantial rise in diabetes cases, projecting that 783 million adults aged 20–79 will be living with diabetes by 2045. Hence, the growing prevalence of diabetes will continue to drive the biosimilar hormones market forward in the years ahead.
Biosimilar Hormones Market Segment Analysis Highlighting Growth Areas
The biosimilar hormones market covered in this report is segmented –
1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types
2) By Application: Research & Biotechnology, Therapeutics, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics
Subsegments:
1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance
2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)
3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management
4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders
5) By Other Types: Thyroid Hormones, Corticosteroids
Biosimilar Hormones Market Industry Trends Shaping Future Revenue Growth
Leading firms in the biosimilar hormones sector are developing new offerings like Sogroya (somapacitan-beco) injection to boost their market profitability. Sogroya (somapacitan-beco) is a prescribed analog of human growth hormone (GH) used for treating individuals with growth hormone deficiency (GHD). For example, in April 2023, Novo Nordisk, a pharmaceutical company based in Denmark, secured FDA approval for a new indication for Sogroya (somapacitan-beco) injection. This approval covers children aged 2.5 years and older who experience growth failure due to insufficient endogenous growth hormone secretion. Sogroya is the only once-weekly growth hormone (GH) therapy designed for both children and adults. The approval was based on results from the phase 3 REAL4 trial, which showed Sogroya’s effectiveness in treating growth hormone deficiency (GHD) in pediatric patients.
Biosimilar Hormones Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the biosimilar hormones market are Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy’s Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt
Access The Complete Biosimilar Hormones Market Report:
Biosimilar Hormones Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the biosimilar hormones market in 2025. The regions covered in the biosimilar hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
